Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | RNF4 | P78317 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10893728 | 0.86 | TRPM8 (0.55) | OPRM1LMNAKDM4EALDH1A1RNF4 | |
| SCHEMBL11226855 | 0.84 | MTNR1A (0.50) | LMNAALDH1A1PDE4BRNF4TRPM8 | |
| SCHEMBL10913927 | 0.83 | LMNA (0.47) | LMNAPDE4BRNF4TRPM8MTNR1A | |
| SCHEMBL3199587 | 0.83 | MTNR1A (0.59) | LMNAMTNR1AMTNR1B | |
| SCHEMBL3199140 | 0.82 | TP53 (0.64) | OPRM1ALDH1A1 | |
| SCHEMBL4948501 | 0.81 | TSHR (0.45) | LMNAALDH1A1PDE4B | |
| SCHEMBL11226870 | 0.79 | TSHR (0.65) | KDM4EALDH1A1PDE4BMTNR1AMTNR1B | |
| SCHEMBL11119371 | 0.79 | PDE4B (0.51) | LMNAKDM4EALDH1A1PDE4BMTNR1A | |
| SCHEMBL12520776 | 0.78 | LMNA (0.46) | LMNAPDE4BRNF4TRPM8MTNR1A | |
| SCHEMBL8916917 | 0.78 | LMNA (0.50) | LMNAPDE4BMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | OPRM1 3972/4885LMNA 133/4885KDM4E 4157/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | OPRM1 4752/4885LMNA 277/4885KDM4E 3885/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | OPRM1 3949/4885LMNA 105/4885KDM4E 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.